Search

Your search keyword '"D’Amico, Thomas A."' showing total 1,701 results
Start Over Author "D’Amico, Thomas A."
1,701 results on '"D’Amico, Thomas A."'

1. The Role of Sleep Apnea in Postoperative Neurocognitive Disorders Among Older Noncardiac Surgery Patients: A Prospective Cohort Study

Author

Devinney, Michael J., Spector, Andrew R., Wright, Mary C., Thomas, Jake, Avasarala, Pallavi, Moretti, Eugene W., Dominguez, Jennifer E., Smith, Patrick J., Whitson, Heather E., Veasey, Sigrid C., Mathew, Joseph P., Berger, Miles, Acker, Leah, Anakwenze, Oke, Anolick, Harel, Attarian, David, Au, Sandra, Ayoub, Chakib, Barber, Matthew, Beach, Rachel, Berchuck, Andrew, Bishara, Katherine, Blazer, Dan, Blennow, Kaj, Bolognesi, Michael, Brassard, Rachele, Brigman, Brian, Browndyke, Jeffrey N., Bullock, William, Bunning, Thomas, Cai, Victor, Cheong, Vanessa, Christensen, Soren, Chung, Stacey, Cohen, Harvey J., Colin, Brian, Cox, Mitchell, D’Amico, Thomas, Davidson, Brittany, Davis, Julia, Deorio, James, Easley, Mark, Eleswarpu, Sarada, Erdmann, Detlev, Feingold, Mariana, Ferrandino, Michael, Gadsden, Jeffrey, Gage, Mark, Ganesh, Arun, Garrigues, Grant, Giattino, Charles, Greenup, Rachel, Habib, Ashraf, Hall, Ashley, Hallows, Rhett, Harpole, David, Hartwig, Matthew, Havrilesky, Laura, Holland, Courtney, Hollenbeck, Scott, Hopkins, Thomas, Houser, Edward, Huang, Samuel, Iboaya, Ehimemen, Inman, Brant, Jiranek, William, Kahmke, Russel, Kawasaki, Amie, Kelleher, Brendan, Kim, Jay, Klapper, Jacob, Klifto, Christopher, Klinger, Rebecca, Knechtle, Stuart, Lagoo-Deenadayalan, Sandhya, Lan, Billy, Lee, Walter, Levinson, Howard, Lewis, Brian, Lipkin, Michael, Mantyh, Christopher, Marlor, Ellie, Martinez-Wilson, Hector, Maxwell, Cory, Migaly, John, Moul, Judd, Murdoch, David, Novick, Thomas, Odom, Kathryn, Ohlendorf, Brian, Olson, Steven, Page, Shannon, Pappas, Theodore, Park, John, Peterson, Andrew, Podgoreanu, Andreea, Polascik, Thomas, Portenier, Dana, Preminger, Glenn, Previs, Rebecca, Rampersaud, Edward, Record, Sydney, Roberts, Kenneth, Robertson, Cary, Roman, Sanziana, Rothman, Jason, Sandler, Aaron, Sata, Siddharth, Scales, Charles, Scheri, Randall, Seyler, Thorsten, Seymour, Keri, Siddiqui, Nazema, Smani, Shayan, Stang, Michael, Stanley, Samuel, Sweeney, Katherine, Syed, Ayesha, Takla, Jeffry, Taormina, Martin, Terrando, Niccolo, Thacker, Julie, Tong, Betty, Toulgoat-Dubois, Yanne, VanDusen, Keith, Waldron, Nathan, Weidner, Alison, Weinhold, Kent, Wellman, Samuel, Williams, David, Wong, Megan K., Yang, Rosa, Young, Christopher, Zani, Sabino, Zetterberg, Henrik, and Zhang, Mimi

Published
2025
Full Text
View/download PDF

2. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Author

Ganti, Apar Kishor P, Loo, Billy W, Bassetti, Michael, Blakely, Collin, Chiang, Anne, D'Amico, Thomas A, D'Avella, Christopher, Dowlati, Afshin, Downey, Robert J, Edelman, Martin, Florsheim, Charles, Gold, Kathryn A, Goldman, Jonathan W, Grecula, John C, Hann, Christine, Iams, Wade, Iyengar, Puneeth, Kelly, Karen, Khalil, Maya, Koczywas, Marianna, Merritt, Robert E, Mohindra, Nisha, Molina, Julian, Moran, Cesar, Pokharel, Saraswati, Puri, Sonam, Qin, Angel, Rusthoven, Chad, Sands, Jacob, Santana-Davila, Rafael, Shafique, Michael, Waqar, Saiama N, Gregory, Kristina M, and Hughes, Miranda

Subjects
Clinical Research, Cancer, Rare Diseases, Lung, Lung Cancer, Good Health and Well Being, Humans, Lung Neoplasms, Medical Oncology, Neoplasm Recurrence, Local, Small Cell Lung Carcinoma, Oncology & Carcinogenesis
Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The "Summary of the Guidelines Updates" section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.

Published
2021

14. Modified Uniportal Approach

Author

Kara, H. Volkan, Balderson, Stafford S., D’Amico, Thomas A., Gonzalez-Rivas, Diego, editor, Ng, Calvin Sze Hang, editor, Rocco, Gaetano, editor, and D’Amico, Thomas A., editor

Published
2019
Full Text
View/download PDF

36. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

Author

Ettinger, David S, Wood, Douglas E, Akerley, Wallace, Bazhenova, Lyudmila A, Borghaei, Hossein, Camidge, David Ross, Cheney, Richard T, Chirieac, Lucian R, D'Amico, Thomas A, Dilling, Thomas, Dobelbower, Michael, Govindan, Ramaswamy, Hennon, Mark, Horn, Leora, Jahan, Thierry M, Komaki, Ritsuko, Lackner, Rudy P, Lanuti, Michael, Lilenbaum, Rogerio, Lin, Jules, Loo, Billy W, Martins, Renato, Otterson, Gregory A, Patel, Jyoti D, Pisters, Katherine M, Reckamp, Karen, Riely, Gregory J, Schild, Steven E, Shapiro, Theresa A, Sharma, Neelesh, Swanson, Scott J, Stevenson, James, Tauer, Kurt, Yang, Stephen C, Gregory, Kristina, and Hughes, Miranda

Subjects
Lung Cancer, Rare Diseases, Lung, Cancer, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Humans, Lung Neoplasms, Mesothelioma, Mesothelioma, Malignant, Pleural Neoplasms, Oncology & Carcinogenesis
Abstract

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

Published
2016

37. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

Author

Ettinger, David S, Wood, Douglas E, Akerley, Wallace, Bazhenova, Lyudmila A, Borghaei, Hossein, Camidge, David Ross, Cheney, Richard T, Chirieac, Lucian R, D'Amico, Thomas A, Dilling, Thomas J, Dobelbower, M Chris, Govindan, Ramaswamy, Hennon, Mark, Horn, Leora, Jahan, Thierry M, Komaki, Ritsuko, Lackner, Rudy P, Lanuti, Michael, Lilenbaum, Rogerio, Lin, Jules, Loo, Billy W, Martins, Renato, Otterson, Gregory A, Patel, Jyoti D, Pisters, Katherine M, Reckamp, Karen, Riely, Gregory J, Schild, Steven E, Shapiro, Theresa A, Sharma, Neelesh, Stevenson, James, Swanson, Scott J, Tauer, Kurt, Yang, Stephen C, Gregory, Kristina, and Hughes, Miranda

Subjects
Lung Cancer, Cancer, Lung, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Docetaxel, Humans, Immunosuppressive Agents, Immunotherapy, Lung Neoplasms, Nivolumab, Practice Guidelines as Topic, Survival Rate, Taxoids, Oncology & Carcinogenesis
Abstract

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

Published
2016

39. Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer:a multi-institutional retrospective cohort study

Author

Deng, Hongsheng, Zhou, Juan, Chen, Hualin, Cai, Xiuyu, Zhong, Ran, Li, Feng, Cheng, Bo, Li, Caichen, Jia, Qingzhu, Zhou, Caicun, Petersen, René H., Rocco, Gaetano, Brunelli, Alex, Ng, Calvin S. H., D’Amico, Thomas A., Su, Chunxia, He, Jianxing, Liang, Wenhua, Zhu, Bo, Deng, Hongsheng, Zhou, Juan, Chen, Hualin, Cai, Xiuyu, Zhong, Ran, Li, Feng, Cheng, Bo, Li, Caichen, Jia, Qingzhu, Zhou, Caicun, Petersen, René H., Rocco, Gaetano, Brunelli, Alex, Ng, Calvin S. H., D’Amico, Thomas A., Su, Chunxia, He, Jianxing, Liang, Wenhua, and Zhu, Bo

Abstract

BACKGROUND: Lymph node (LN) dissection is a common procedure for non-small cell lung cancer (NSCLC) to ascertain disease severity and treatment options. However, murine studies have indicated that excising tumor-draining LNs diminished immunotherapy effectiveness, though its applicability to clinical patients remains uncertain. Hence, the authors aim to illustrate the immunological implications of LN dissection by analyzing the impact of dissected LN (DLN) count on immunotherapy efficacy, and to propose a novel 'immunotherapy-driven' LN dissection strategy. MATERIALS AND METHODS: The authors conducted a retrospective analysis of NSCLC patients underwent anti-PD-1 immunotherapy for recurrence between 2018 and 2020, assessing outcomes based on DLN count stratification. RESULTS: A total of 144 patients were included, of whom 59 had a DLN count less than or equal to 16 (median, IQR: 11, 7-13); 66 had a DLN count greater than 16 (median, IQR: 23, 19-29). With a median follow-up time of 14.3 months (95% CI: 11.0-17.6), the overall median progression-free survival (PFS) was 7.9 (95% CI: 4.1-11.7) months, 11.7 (95% CI: 7.9-15.6) months in the combination therapy subgroup, and 4.8 (95% CI: 3.1-6.4) months in the immunotherapy alone subgroup, respectively. In multivariable Cox analysis, DLN count less than or equal to 16 is associated with an improved PFS in all cohorts [primary cohort: HR=0.26 (95% CI: 0.07-0.89), P =0.03]; [validation cohort: HR=0.46 (95% CI: 0.22-0.96), P =0.04]; [entire cohort: HR=0.53 (95% CI: 0.32-0.89), P =0.02]. The prognostic benefit of DLN count less than or equal to 16 was more significant in immunotherapy alone, no adjuvant treatment, pN1, female, and squamous carcinoma subgroups. A higher level of CD8+ central memory T cell (Tcm) within LNs was associated with improved PFS (HR: 0.235, 95% CI: 0.065-0.845, P =0.027). CONCLUSIONS: An elevated DLN count (cutoff: 16) was associated with poorer immunotherapy efficacy in recurrent NSCLC, especially

Published
2024

49. Predictors of staging accuracy, pathologic nodal involvement, and overall survival for cT2N0 carcinoma of the esophagus

Author

Atay, Scott M., Correa, Arlene, Hofstetter, Wayne L., Swisher, Stephen G., Ajani, Jaffer, Altorki, Nassar K., Blackmon, Shanda H., Blackstone, Eugene H., Rice, Thomas W., Crabtree, Traves D., D'Amico, Thomas A., Darling, Gail E., DeMeester, Steven R., DeMeester, Thomas R., Worrell, Stephanie G., Ferri, Lorenzo E., Gaissert, Henning A., Krasna, Mark J., Lerut, Antoon, Nafteux, Phillippe, Moons, Johnny, Little, Alex G., Low, Donald E., Carrott, Phillip W., Schmidt, Henner M., Miller, Daniel, Nason, Katie S., Luketich, James D., Orringer, Mark B., Chang, Andrew C., Rizk, Nabil P., Salo, Jarmo A., Schneider, Paul M., Smithers, Bernard Mark, Vallböhmer, Daniel, van Lanschot, J.J., Varghese, Thomas K., Watson, Tom J., Peters, Jeff H., and Yang, Stephen C.

Published
2019
Full Text
View/download PDF

50. Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of survival and patterns of recurrence in a prospective, phase II single-arm trial.

Author

Karukonda, Pooja, primary, LaBella, Dominic, additional, Czito, Brian G., additional, Duffy, Eileen, additional, Uronis, Hope Elizabeth, additional, D'Amico, Thomas A., additional, Strickler, John H, additional, Niedzwiecki, Donna, additional, Willett, Christopher, additional, and Palta, Manisha, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results